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ABSTRACT 
Smoking is a risk factor for a number of diseases including chronic obstructive pulmonary 
disease (COPD) and rheumatoid arthritis (RA). Cigarette smoke initiates an inflammatory 
response which leads to structural changes in the airways and in the lung parenchyma. The 
present work was undertaken in order to shed light on pulmonary manifestations of two 
common smoking-related diseases, COPD and RA. 
A retrospective review on bronchoalveolar lavage (BAL) constituents, encompassing 132 
smokers with normal lung function and 44 ex-smokers, was performed. Two hundred and 
ninety- five neversmokers served as reference group. The median (5-95 percentile) cell 
concentration in smokers were 382.1 (189.7-864.3) X 106 /L which was higher compared 
to the neversmokers. The majority of cells were alveolar macrophages (median 96.7%; 
range 73.2-99.6%, lymphocytes (2%; range 0.2-26%) and neutrophils (0.6%; range 0-6%). 
Cell concentration was positively correlated to cumulative smoking history. 
One hundred and five patients with newly-diagnosed RA, (70% ACPA+), underwent high 
resolution computer tomography (HRCT) examination and a sub group of 23 patients also 
performed bronchoscopy and BAL. A group of 43 non-diseased smokers and never 
smokers were examined as control. Parenchymal lung abnormality on HRCT was found in 
63% of ACPA+ compared to 37% ACPA- RA patients, 30% control regardless of smoking 
status. The level of ACPA was higher in BAL fluid than sera in ACPA+ RA patients.    
Forty smokers with normal lung function, (mean 35 pack-years), 40 healthy never-smokers, 
and 40 COPD-patients of GOLD, I-II, (38 PY), performed HRCT. In addition BAL was 
performed. Percentage of pixels between -750- -900 HU (%HDS) was calculated. Lung 
density was increased in smokers (44.0% ± 5.8%) compared to never smokers (38.3 ± 
5.8%), p<0.001. Cell concentration in BAL was positively correlated to lung density in 
smokers (r=0.50, p<0.001). Females had denser lungs than males. 
Regional air trapping was assessed on expiatory HRCT on 40 never-smokers, 40 smokers 
and 40 COPD-patients. Emphysema, micronoduli, bronchial wall thickening was 
determined on inspiratory HRCT. Air trapping index (AI) was quantified as the ratio of 
mean lung attenuation at expiration and inspiration. Regional air trapping was present in 
63% of smokers and 45% of never smokers. Smokers with visible regional air trapping had 
an AI of 0.81, while smokers without visible air trapping had an AI of 0.91. A negative 
correlation between AI and neutrophils in BAL was observed. Smokers with regional air 
trapping had better lung function and less emphysema compared to smokers without. 
 We demonstrate inflammatory and structural changes in the lungs in smokers by means of 
HRCT and BAL. These changes are apparent even before clinical symptoms occur. The 
studies highlight the heterogeneity in smoking-related diseases which may be of importance 
in terms of disease progression and patient phenotypes.   
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1 INTRODUCTION 
1.1 HISTORICAL BACKGROUND 
Tobacco usage by Native Americans has a long history. In higher dosages as a hallucinogen 
tobacco was used only by “experienced” medicine men and shamans in ceremonies. It was 
not until the 18th century that tobacco emerged as a big commercial product and 
consequently an important financial resource for the United States government. Strong 
commercial interests in a free market and the opportunity for the tobacco industry to 
advertise easily via newspapers and films increased tobacco’s popularity all over the word 
by the end of the 1930s. Health concerns regarding serious damage related to cigarette 
smoking became apparent through publications by Doll et al. in the British Medical Journal 
in the early 1950s, linking smoking to lung cancer [1, 2]. Increased mortality due to airway 
dysfunction and bronchitis symptoms and the association of airway mucus hypersecretion 
with emphysema were suggested in autopsy studies by Thurlbeck et al in 1963 [3]. 
 
1.2  SMOKING-RELATED DISEASES 
 During the past few decades a huge body of knowledge has been gathered, increasing our 
awareness of tobacco-related diseases. Among these, COPD is the most serious global 
health issue, accounting for almost 30% of all mortality attributed to tobacco smoking. 
This figure was estimated from nearly two million deaths in 2005 and COPD is expected to 
advance from the fifth to the fourth leading cause of death by 2030 [4, 5]. COPD is also a 
significant cause of disability, hospitalization and health-care costs worldwide [6]. 
Cigarette smoke affects almost every aspect of health, including the cardiovascular system 
with increased risk of heart failure and stroke. These together with cancer and respiratory 
diseases account for most tobacco-related deaths world-wide [7-10]. The prevalence of 
smoking-related malignancy is estimated to about 5%, mostly lung adenocarcinoma and 
other epithelial tumors [11, 12]. Smoking increases the prevalence of bladder cancer, 
mesothelioma and cervical cancer, and is a co-factor in several other malignant conditions 
[7, 8, 13]. Further, smoking has been suggested to initiate autoimmunity in genetically-
susceptible individuals [14, 15]. Cigarette smoke has been associated directly to some 
diffuse parenchymal lung diseases (DPLD) [16], such as desquamative interstitial 
pneumonia (DIP) and respiratory-bronchiolitis-associated interstitial lung diseases (RB-
ILD) and pulmonary Langerhans cell histiocytosis (PLCH). These conditions are treatable 
by smoking cessation and steroid therapy [17-20]. An association between cigarette smoke 
and increased risk of developing idiopathic pulmonary fibrosis (IPF) in former and current 
smokers has been shown in some studies [20-27] but not all [28].       
 
1.3 EFFECT OF SMOKING ON THE IMMUNE SYSTEM 
Cigarette smoke contains several thousand highly toxic components which affect the 
immune system in many different ways. Some agents in cigarette smoke are high potential 
carcinogens, several are pro-inflammatory and others such as nicotine and carbon 
monoxide have immune-suppressive effects [2, 29-34]. Cigarette smoke damages 
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respiratory epithelium directly with increased permeability, compromising the physical 
barrier against environmental pollutants and virus and bacteria [31,35, 36]. The normal 
process of repair and the apoptotic system is damaged by the oxidation of epithelial 
membrane lipids and the induction of extensive single-stranded DNA breaks [37]. Further, 
smoking activates alveolar macrophages, a key player in front-line defense against 
microbial agents. These increase in number and produce pro-inflammatory mediators that 
consequently recruit other inflammatory cells such as neutrophils and lymphocytes to the 
site of injury [29, 30, 38, 39]. Cigarette smoke compromises the ability of alveolar 
macrophages to phagocyte bacteria and clear apoptotic cells [40, 41]. This promotes a more 
sustained inflammatory process in the respiratory tract [42, 43]. The number and activity of 
natural killer cells (NK), an important element of the innate host defense against 
microorganisms, is reduced, thereby linking this effect to an increased risk of cancer and 
infections [44, 45]. A decreased level of immunoglobulin classes, except IgE, in smokers is 
reported in human and animal studies [33]. Skewing of several important elements in the 
immune system due to exposure to active or passive smoking together with individual 
susceptibility may explain the link between cigarette smoke and many diseases [43, 46]. 
1.4 SMOKING AND COPD 
Chronic obstructive pulmonary disease is a complex disease where the most important 
environmental risk factor, tobacco smoke, induces an exaggerated inflammatory response in 
the lungs of genetically-susceptible individuals [5, 47-50]. The ongoing inflammation 
destroys the lung parenchyma (emphysema) and causes fibrosis and inflammation in small 
airways (remodeling), which subsequently contributes to increased airways resistance by 
narrowing and constricting the lumen [16, 51, 52]. Parenchymal destruction and increased 
alveolar size reduce elastic recoil and this in combination with remodeling contributes to not-
fully-reversible airway obstruction [16, 53-58]. Smoking intensity is associated with decline 
in rate of FEV1 and increased frequency of exacerbation in COPD patients [59-62]. Overspill 
of inflammation from the lungs has been suggested as the main cause of systemic 
inflammation, increasing cardiovascular disease, osteoporosis, and diabetes [63, 64]. There 
are still limitations in our understanding of the underlying mechanisms behind COPD. 
Despite a chronic inflammation characterized mainly by neutrophils and macrophages in the 
small airways of the all smokers, for unknown reasons, some develop progressive 
emphysema and severe airway pathology while others manage to continue with airway 
inflammation with slower functional changes, which may stay subclinical [65, 66]. 
Neutrophils are found frequently in the small airways of smokers and correlate to the amount 
of smoking [30, 66, 67]. These cells may be attracted to the site by chemotactic factors 
released by activated macrophages in the respiratory bronchioles and alveolar sacs in 
epithelial lining fluid [67, 68].  
The pathogenic role of neutrophils in smoking-related lung diseases is a matter of 
controversy. The number of neutrophils, the marginal pool, rises in the lung capillary in the 
presence of cigarette smoke [69] and correlates to the rate of decline in forced expiratory 
volume (FEV1) [69, 70]. However other investigators have found an inverse relation between 
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the number of neutrophils and the degree of tissue destruction in the lungs (i.e. emphysema), 
suggesting neutrophilic inflammation as a sign of better-preserved lung parenchyma [71, 72]. 
Nevertheless, macrophage and neutrophil infiltration seems to be orchestrated in an acute and 
non-specific defense against cigarette smoke injury, while lymphocyte infiltration with 
predominantly CD8+ cells in the lung may indicate a more advanced and specific humoral 
immune response with potential lung injury [66, 73-77]. The exact role of CD8+ cells in the 
pathogenesis of obstructive lung disease is not clear but an association between the number of 
CD8+ cells, and the severity of airway obstruction and the degree of alveolar destruction and 
apoptosis of alveolar epithelium, has been shown in smokers [70, 78]. A study on surgically 
resected lung tissue from smokers showed that several inflammatory cells including 
macrophages, neutrophils, lymphocytes and eosinophils correlated equally to the degree of 
tissue destruction with emphysema with no predominance of any single inflammatory cell 
[79]. 
  
1.5 SMOKING AND RHEUMATOID ARTHRITIS 
Rheumatoid arthritis (RA) is a chronic, systemic autoimmune disease characterized by 
multiple joints inflammation and destruction. Although the exact etiology of the disease is 
unknown, some data indicate a link to cigarette smoke [80-82]. Women are more 
susceptible than men and the prevalence among the general population is estimated to 0.5- 
1% [81]. Pulmonary involvement is a main extra-articular manifestation of RA with major 
impact on morbidity and premature mortality in this patient group [83-87]. Many structures 
in the lungs including airways, pulmonary vasculature, and pleura may be involved to 
differing extents but the most serious condition, with high mortality, is RA-associated 
intestinal lung disease (RA-ILD) [87, 88]. A high prevalence of pulmonary changes in 
newly-diagnosed RA, and indeed even prior to the onset of symptomatic inflammatory 
arthritis, has encouraged the hypothesis that the lungs may be a potential site of initiating 
autoimmunity [89-94]. Anti-cyclic citrullinated peptide antibody (ACPA) is a specific 
autoantibody which is highly predictive of disease severity and progression and is also a 
predictive marker of future disease development in the sub-group RA with (ACPA+) [95-
97]. ACPA and lung changes together in newly-diagnosed RA, or prior to disease onset, 
provide further support for the hypothesis that in some susceptible individuals 
autoimmunity can be initiated at an extra-articular site, presumably the lungs, under the 
influence of smoking or other environmental agents[15, 98]. Elevated citrullinated peptides 
and corresponding catalyzing enzyme, peptidylarginine deiminase (PAD2) in 
bronchoalveolar lavage obtained from smokers’ lungs may further strengthen this 
hypothesis [14]. A link between smoking and the initiation of an immune reaction with 
citrulline-modified protein with HLA-DR-shared epitope genes has been suggested [15]. 
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2 ASSESSMENT OF INFLAMMATION AND STRUCTURAL CHANGES IN THE 
LUNG 
2.1 QUANTIFICATION OF LUNG PARENCHYMA ON COMPUTED 
TOMOGRAPHY  
Recent advances in computed tomography technique, along with our understanding of the 
various patterns of high-resolution computed tomography (HRCT) features in specific 
pathological conditions in the lung, have revolutionized the utility of this imaging modality. 
With excellent spatial resolution and high signal-to-noise ratio CT is indispensable for 
medical imaging of the lungs. It is used broadly in both the clinic and research [99, 100]. 
We are able nowadays to obtain detailed, thin section images of very high quality within 
just a few seconds of breath-holding, using multi-detector computed tomography (MDCT). 
Information from isotropic voxels can be added automatically to obtain both lung volume 
and attenuation reliably [101-103] (Figure 1). Further detailed morphological information 
can be extracted by reformatting sagittal and coronary images from axial planes.   
Attenuation values of the lungs are measured in Hounsfield units (HU). These are 
conventionally set to zero for pure water and -1000 HU for pure air and 40 HU for blood. 
Linear attenuation values from voxels average and provide information for quantitative 
assessment of the lung tissues. Density and structural measurements of the lung 
parenchyma and airways obtained from contiguous thin-slice images offer a unique 
opportunity to evaluate the distribution and presence of lung pathology in vivo [104-110].  
Figure 1: Software delineates lung tissues from surrounding structures and calculates 
values for lung volume and attenuation   
 
Attenuation values are proportional to tissue density determined by the relative amounts of 
lung tissue, blood and air. In emphysema the number of voxels with lower attenuation 
values increases as a result of tissue loss. Attenuation values lower than -950 HU on slices 
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obtained on HRCT have been validated to represent microscopic and macroscopic 
emphysema [111-113]. The threshold of -910 HU was used originally on thicker slices 
obtained from conventional CT [114]. Another method which has shown correlation to 
emphysema in pathological specimens was originally to use attenuation values lower than 
the 5th percentile on a frequency-distribution curve as a measure of emphysematous tissue 
[115]. This approach has been modified in recent studies to the 15th percentile and has been 
implemented in clinical studies [108, 110, 116]. Both methods estimate the extent of 
disease reasonably and are recommended for cross-sectional studies, while the “15th” 
method is recommended in longitudinal studies [108, 116, 117]. CT densitometry is a 
valuable tool in assessing lung structure changes and provides very important data for 
understanding the pathogenesis of smoking-related lung diseases. Analogously with regions 
of lower attenuation as a surrogate for emphysema, lung parenchyma with increased 
attenuation can be used to indicate the intensity of inflammation. However, studies in this 
field are very limited [27]. CT densitometry has several limitations, including technical 
divergence between scanners, lack of a standard method for analyzing lung parenchyma 
and airways, degree of inspiration, and exposure of subjects to ionizing radiation, [118-
120].  
 
2.2 QUANTIFICATION OF AIRWAYS ON CT 
Assessment of changes in the airways wall and lumen dimension due to inflammation and 
submucosal fibrosis –”remodeling” – has attracted much attention recently [121-123]. This 
method is technically more challenging than parenchymal lung densitometry 
measurements. This is because the diameters of small airways (i.e.  <2mm), which are the 
epicenter of inflammation in smokers and COPD patients, is below the resolution of CT 
[121, 124, 125]. Despite the technical complexity of the method, Nakano et al. Showed that 
the wall thickness in small airways measured in histological specimens correlated to that in 
intermediate airways in the right apical bronchus (i.e. diameter nearly 7.5mm) measured 
with CT [123]. Hasegawa et al, refining the method using three-dimension reconstruction 
of the airways, measured wall thickness down to sixth-generation airways. They found a 
stronger correlation between wall thicknesses with FEV1 in smaller airways (sixth 
generation) than to intermediate (third generation). These studies indicate that small and 
large airways build an anatomical continuity, with coexisting morphological abnormality in 
both. Despite very important progress in this area the major obstacle, the limited resolution 
of current scanners for measuring small airways, is still unresolved. Consequently the 
method needs further refinement before it can be implemented clinically [126].  
 
2.3 MORPHOLOGICAL FEATURES OF THE LUNG ON HRCT 
HRCT findings play a central role in the detection and classification of small airways 
diseases and when correlated with clinical findings they can considerably improve 
diagnostic accuracy. The secondary pulmonary lobule (SPL) is the smallest functioning 
subunit of the lung separated by connective tissue septa. Each SPL is 1 -2.5 cm in diameter 
and contains a bunch of small airways radiating from central lobular bronchiole (1 mm in 
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diameter). SPL are very important anatomical landmarks which are not visible on normal 
HRCT. Bronchioles which are also invisible on normal HRCT become visible in the central 
part of the SPL with small airways disease due to infiltration of inflammatory cells and 
increased density in or around the bronchioles. These CT signs of small airways disease 
appear as faint ground-glass opacities [127]. Regional air trapping, which appears on end-
expiratory thin-section CT, is characterized as regions with low attenuation area, due to 
under-ventilation. It follows the geographical border of SPL and may indicate small 
airways disease [128, 129]. Air trapping is a frequent finding on end-expiratory scans 
obtained from smokers with normal lung function and normal inspiratory scans, and it may 
be an indirect sign of small airways disease. Air trapping also appears sometimes within a 
few SPL in even apparently healthy never-smokers [130-132]. More serious conditions 
with widespread airways diseases such as infiltrative lung disease, occlusive pulmonary 
vascular disease and allergic alveolitis appear as extensive multi-lobular air trapping - the 
“mosaic pattern” – usually on both inspiratory and expiratory HRCT scans and mostly 
accompanied by serious respiratory symptoms [133]. Respiratory-bronchiolitis-associated 
interstitial lung disease (RB-ILD) overlaps pathologically with desquamating intestinal 
pneumonia (DIP). Both diseases are strongly related to smoking intensity and characterized 
histologically by sub-mucosal fibrosis and inflammation with accumulation of pigmented 
macrophages in bronchioles and alveolar ducts and spaces. The HRCT finding in these 
conditions appears as several stigmata including air trapping, micronoduli and patchy 
ground-glass opacity [134]. The two latter findings were shown to correspond, in 
pathological specimens, to accumulation of macrophages in respiratory bronchioles and in 
alveolar space, respectively [135]. 
2.4 VISUAL ASSESSMENT OF EMPHYSEMA AND AIRWAYS 
The development of emphysema in the lungs of smokers is generally recognized and 
seldom causes interpretation difficulties on HRCT [104]. Centrilobular or (centriacinar) 
emphysema refers morphologically to the destruction of respiratory bronchioles located at 
the center of the secondary pulmonary lobules, while panlobular or (panacinar) indicates 
destruction of the whole acinus [136-138]. The former is strongly associated with cigarette 
smoking and associated with more small airways inflammation, and appears predominantly 
in the upper lobes while the latter is linked to α1-antitrypsin deficiency with lower-lobe 
predominance [136, 139]. It is likely that small airways disease spreads centrifugally and 
destroys the alveolar walls attached to the respiratory bronchioles, subsequently appearing 
on CT as centrilobular lesions [65, 136, 139]. These lesions are easily detectable on HRCT 
scans as small areas of low attenuation usually without walls, contrasting with the 
surrounding parenchyma with normal attenuation [140-142] (Figure2). With panlobular 
emphysema the entire secondary lobules are destroyed and the emphysema appears as a 
homogeneous pattern of low attenuation which can involve the entire lung [16, 143-145]. 
Several studies have documented the accuracy of CT in assessing the presence and extent 
of even mild emphysema with good correlation with pathological specimens [112, 142, 
146]. Emphysema is detected in the lungs of a majority of smokers with no significant 
airways obstruction. Sometimes one-third of the lung can be destroyed by emphysema 
without any significant clinical symptom or reduced lung function [147, 148] [149]. In 
contrast to the accuracy of visual assessment of emphysema on HRCT, the judgment of 
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bronchial wall thickening and bronchial dilatation is more highly associated with inter-
observer variation than any other morphological signs on HRCT [150, 151]. Nevertheless, 
with correct window settings, bronchial wall thickening is widely observed in smokers 
compared to never-smokers and it may be a typically widespread sign of HRCT in smokers 
with chronic bronchitis [127]. Bronchial wall thickening In COPD patients is partly 
associated with degree of airways obstruction and symptoms [152, 153]. Interpretation of 
bronchial dilatation, a cardinal sign of bronchiectasis, is based on approximate size equality 
between external diameters of bronchi and the adjacent artery. Although easy to remember, 
this rule is based on a study of healthy subjects with widely ranging bronchial sizes, with 
mean ratio of 0.98, range, 0.53-1.39 [154]; thus it should be used in the context of other 
clinical information. 
 
 
Figure 2: Centrilobular emphysema, easily distinguishable, in the central part of right and 
left over lobs of a 51 year-old female smoker  
 
2.5  BRONCHOSCOPY AND BRONCHOALVEOLAR LAVAGE BAL    
 
Considerable progress has been achieved since the introduction of rigid bronchoscopy by C. 
Jackson in 1904 and flexible fiber bronchoscopy by S. Ikeda in 1967. Flexible fiber 
bronchoscopes are available with different seizes and equipment to obtain biological 
material for both clinical and research purposes. Bronchoscopy with bronchoalveolar 
lavage (BAL) is a minimally-invasive procedure performed usually with outpatients. After 
application of local anesthesia the bronchoscope tip is wedged in a third- or fourth-
generation-segmental bronchus (Figure3).The middle lobe or lingula is the usual site of 
lavage, because it is easily accessible with better fluid retrieval, when BAL is performed for 
research purposes and with diffuse or disseminated parenchymal abnormality.  
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BAL may be performed in other specific sites or in several when regional radiographic 
heterogeneity is present on HRCT [155, 156]. A number of 20-60 ml aliquots of body-
warmed saline with a total volume of 100-300 are normally instilled and subsequently 
retrieved. Suction should be gentle to avoid airway collapse. Especially low suction should 
be applied with emphysema due to lack of airway support [157]. More than 40% of the 
instilled volume of the fluid should be recovered [156, 158, 159]. BAL has a low 
complication rate with minor discomfort such as coughing during the procedure or fever 
chills. The latter are associated to larger volumes, and may occur hours after BAL due to 
cytokine release [160, 161].  
The gross visual appearance of BAL may be highly suggestive or virtually diagnostic of 
specific rare disease. One example is bloody BAL with diffuse alveolar hemorrhage 
(DAD), which has many different causes; or with pulmonary alveolar proteinosis [58] 
where the BAL fluid appears as cloudy, milky or light brown [162, 163].  
BAL-cell profiles in smokers have been investigated in several studies confirming a four-
to-six fold increase in cell concentration compared to never-smokers. This is mainly due to 
increase in the number of macrophages [14, 164-167]. Neutrophils and eosinophils are 
generally elevated in smokers [156, 168, 169]. An extreme increase in neutrophil 
percentages may indicate infection or diffuse lung injury while a percentage of eosinophils 
higher than 25% is likely caused by eosinophilic pneumonia or other eosinophilic lung 
disease [170-174]. BAL lymphocytes higher than 25% may indicate ILD related to 
granuloma, particularly when the CD4/CD8 ratio is more than 3.5 with sarcoidosis [167, 
175]. Although BAL is a useful and well-tolerated clinical tool it cannot stand alone and 
should be interpreted in the context of clinical and radiographical information. BAL is 
particularly useful to rule out infection or 
hemorrhage as a cause of parenchymal 
infiltration on HRCT. As a research tool BAL 
has provided valuable insight into the 
pathogenesis of many rare lung diseases [176, 
177].    
 
 
 
Figure 3: Simplified illustration of BAL 
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3 AIMS 
The general aim of the work presented in this thesis was to assess inflammation and 
structural changes in the lungs of smokers and patients with COPD (GOLD I, II) and RA 
patients in the early stage of disease  
The specific aims were: 
-to study the effect of smoking on BAL fluid recovery and cell counts in smokers and ex-
smokers with normal lung function, in order to establish reliable reference values for better 
interpretation of BAL cell counts in clinical and research settings;  
-to assess the morphological features of CT scans in newly diagnosed RA and correlate 
these changes to the presence of ACPA and smoking status;  
-to quantify inflammation in the lungs of smokers and COPD patients (GOLD I, II) current 
and ex-smokers by means of CT densitometry and BAL-cell differential counts, and 
-to categorize morphological changes in the lungs of smokers, healthy controls and COPD 
patients (GOLD I, II) using CT scans obtained with expiration and inspiration with focus on 
air trapping and its correlation to BAL cells as a measure of small airways inflammation. 
4 PAITENTS AND METHODOLOGY    
A short description of the participants and the methods employed in the four studies 
underlying this thesis is presented here. Roman numerals (I-IV) refer to the corresponding 
papers. 
Participants in study (I)  
BAL cell counts and fluid recovery were studied retrospectively. The study encompassed 
132 smokers with normal lung function (48/84, males/females, M/F) of mean age 39 years 
and smoking history of mean value 20.8 (PY), plus 44 ex-smokers (16/28, M/F), mean age 
39 and smoking 5.3 (PY). A group of 295 (132/163, M/F), healthy never-smokers, an 
account of whom was published separately by Olsen et al [178], served as controls. All 
participants had been served as healthy controls in different investigations involving 
bronchoscopy and BAL between 1990 and 2009 in our department. 
Participants in study II 
Study II emerged as a result of collaboration between the Department of Rheumatology and 
the Department of Pulmonology at Karolinska University Hospital. A number of 105 
patients with newly-diagnosed RA, (30/75, M/F), 70% ACPA+, 29% were current smokers, 
74% ex-smokers and 26% never-smokers. A number of 43 age and gender matched, 67% 
current smokers with normal lung function and 33% never smokers, were included as 
controls. Control subjects were selected from participants in studies III and IV. 
Participants in studies III, IV 
Data analyzed in two studies (III, IV) were obtained from the same subjects. Forty smokers 
with normal lung function (20/20, M/F), mean age 54, mean smoking history 35 (PY), 40 
healthy never-smokers, mean age 57, plus 40 COPD (GOLD, I-II), mean age 59, mean 
smoking 38 (PY), 31 current smokers and nine ex-smokers) were recruited, mainly by 
advertisement. None with any significant medical condition, infection, allergy or 
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respiratory disease except COPD were allowed to participate. Corticosteroid in any form 
was not allowed. 
Pulmonary function test – studies I, II, III, IV 
Participants in study I performed dynamic spirometry only if they were smokers and older 
than 40 years of age. Only subjects with FEV1/FVC>0.7 and FEV1>80% were included. 
Participants in studies II, III, and IV performed both dynamic spirometry and body 
plethysmography with measurement of DLCO. All measurements were performed in a 
standard way and were reported as percentages of predicted values according to 
international recommendations. 
Bronchoscopy and BAL – studies I, II, III, IV 
Bronchoscopy and BAL was performed on all participants in studies I, III, and IV, and 23 
patients with RA, study II, according to a standard procedure in our department. The 
bronchoscopy procedure has been detailed earlier.    
Preparation of BAL fluid and cells – studies I, II, III, IV 
Fluid collected after BAL was kept on ice and analyzed immediately in the Lung Research 
Laboratory at our department. Debris was separated by filtration of BAL fluid through a 
Dacron net and then the volume was registered. A cell pellet was prepared after 
centrifugation and re-suspended in RPMI medium. The cells were counted in a Bűrker 
chamber. For differential counting, cytocentrifugation was employed prior to cell staining 
with May-Grűevald Giemsa. 
 II Immunohistochimical analysis (II) 
Levels of IgG and IgA against ACPA in serum and BAL fluid were measured using a 
commercial kit. The total concentrations of IgG and IgA in serum and BAL were measured 
at the clinical immunology laboratory at Karolinska University Hospital.   
 
Quantitative image analysis on HRCT – studies III, IV 
Inspiratory and expiratory HRCT scans without contrast medium were obtained from all 
participants. A semi-automatic program was employed to differentiate lung parenchyma 
from surrounding structures by choosing predetermined attenuation values between -300 
and -1024 HU, representing whole-lung parenchyma. Calculating the value of voxels 
generated mean lung attenuation and lung volume. In study III, the percentage of lung 
volume with attenuation between defined thresholds of -750 and -900 HU, labelled 
percentage of lung volume with higher-density HDS % (Figure 6),  was calculated 
separately and was correlated to BAL cell differential cell counts. In study IV, the air 
trapping index (AI), was calculated as the ratio of mean lung attenuation at expiration and 
inspiration.  
Qualitative image analysis on HRCT – study IV 
All images were anonymized and then assessed in a random order independently by two 
reviewers blinded to all subject data. Morphological assessments including regional air 
trapping were judged on expiratory scans while emphysema, micronoduli and bronchial 
wall thickening and solid nodules were judged on inspiratory HRCT scans.  
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5 RESULTS AND DISCUSSION 
Paper I 
In Study I we found that both total cell number and cell concentration in BAL from 
smokers showed a four-fold increase with a wide inter-individual range. Macrophages 
accounted for almost 96% of the cells in smokers, while the corresponding percentages for 
never-smokers and smokers-and-ex-smokers were 90% and 88% respectively. Neutrophils 
and eosinophils were increased in smokers compared to never-smokers and ex-smokers 
while lymphocytes did not differ significantly. Cell concentration correlated positively with 
smoking history expressed as pack years (PY).The percentage of recovered BAL fluid 
decreased with increasing age and was significantly lower in male smokers than in female. 
BAL as a diagnostic tool  
In agreement with previous studies we found that smoking had a profound effect on BAL 
cell counts, especially macrophages [176, 177]. The increased number of BAL cells was 
dose-related and increased positively with increased pack years. This result agrees with that 
of Rennard et al who showed that reduction in cigarette smoking resulted in fewer 
macrophages and neutrophils [178]. The number of cells in BAL may represent the 
intensity of small airways inflammation in smokers, and this may differ widely depending 
on each subject’s unique immune reaction to cigarette smoke. This inflammatory reaction 
seems mainly reversible at least in terms of cell number, according to our observation from 
ex-smokers. Subclinical inflammation in smokers is silent due to low resistance in small 
airways, and thus is undetectable on spirometry until a significant decline in lung function 
has occurred.   
Many previous studies dealing with BAL in smokers are small and utilize different 
techniques particularly regarding instilled lavage volume. Despite technical inconsistency 
their results are consistent and in agreement with ours [176, 179, 180]. A wide range of cell 
numbers was obtained from smokers’ BAL, and although this afforded very valuable 
information it cannot stand alone as diagnostic for smoking-related interstitial lung 
diseases. There is a risk of overlap between smokers with clinically significant symptoms 
and those with preclinical inflammation. Information from BAL in combination with 
radiographic signs and clinical symptoms may, however, provide specific diagnoses 
without the employment of invasive diagnostic procedures.          
 
 
 Paper II 
The main focus of study II was to investigate structural lung changes on HRCT in a group 
of newly-diagnosed RA patients and, further, to correlate these structural changes with 
ACPA antibodies and smoking history. Structural changes were significantly higher in the 
lungs of all RA patients regardless of ACPA status than in controls. ACPA-positive RA 
patients had significantly higher morphological changes in the lung than ACPA-negative 
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ones, regardless of smoking status. Concentration of ACPA was significantly higher in 
BAL than in sera in ACPA-positive patients. 
Is the lung the primary site for autoimmunization with ACPA-positive RA? 
The majority of our RA patients had lung abnormalities on HRCT (54%) without any 
significant clinical symptoms. This indicates that HRCT is a powerful imaging tool to 
reveal early structural changes in the lung. Most of these changes were limited to a small 
portion of the lung, and barely affected lung function or caused clinical symptoms at this 
early stage (Figure 4). These changes, however, in correlation to ACPA antibodies, 
strengthen the hypothesis that the lung can somehow be involved in autoimmunization. It is 
however possible that these ACPA patients had more intensive systemic inflammation and 
thereby more structural changes in the lung. In a study on subjects with positive ACPA 
prior to onset of inflammatory arthritis Demoruelle et al [87] found that pulmonary changes 
in76% of ACPA-positive subjects, of whom two developed inflammatory arthritis after a 
follow-up period of 13 months. The ability of lung immunity to react against inhaled 
pollutants such as cigarette smoke may initiate autoimmunity in genetically vulnerable 
subjects. Inducible bronchus-associated lymphatic tissue (iBALT) with abundant B 
lymphocytes in the submucosal airways of RA, and Sjögren’s syndrome with pulmonary 
involvement and reaction between IgG and citrullinated fibrinogen, was identified in 
another study [181].   
 
Figure 4: Examples of typical lung abnormalities in two patients with newly diagnosed RA, 
on the left scan mild area of fibrosis predominantly sub- pleural, on the right scan  air 
trapping visible in the dependent and sub-pleural area of the lung  
 Paper III 
In study III we demonstrated that lung density measured on HRCT, expressed as HDS%, as 
a surrogate for local inflammation, is correlated with total cell concentration obtained with 
BAL. Smokers had denser lungs than never-smokers and COPD patients. Lung density in 
females was higher regardless of smoking status but the difference diminished after 
correction for height.   
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 Increased lung density and cell concentration in BAL mirrors inflammation  
Lung density measurement algorithms have been developed according to the percentage of 
pixels with lower attenuation, called the density mask, for quantification of emphysema 
[112, 114]. However, there is only one study, by Lederer et al [25], where pixels with 
higher attenuation are investigated in relation to subclinical lung diseases. Lung density is a 
product of tissue volume, blood, cells and decrease of air. With inflammation in the lung 
the number of inflammatory cells increases and may indicate an overall increase in intensity 
of inflammation in lung parenchyma, and consequently increased lung density (Figure 5). 
A uniform increase in lung density on HRCT in smokers without apparent lung disease is 
difficult to detect with the naked eye. Analogue with pixels with lower attenuation on the 
distribution curve as measurement for emphysema with shift on the frequency distribution 
curve to the left, with increased inflammation and consequently higher density the curve 
will shift to the right (Figure 6). This method might be useful in smokers in an early 
preclinical stage of disease. The major challenge when measuring parenchymal 
inflammation in COPD is the net 
effect of increased density 
(inflammation) against decreased 
density (destruction). This became 
obvious in our study of COPD 
patients. In larger groups of COPD 
patients however this may be a useful 
method to categorize different sub-groups 
depending on lung density and smoking 
status.      
 
 
Figure 6: Attenuation values between -750 to -900 HU are highlighted on the frequency 
distribution curve 
 
Paper IV 
In study IV we investigated regional air trapping visible on expiratory HRCT in smokers 
with normal lung function as a measure of small airways disease. Further, we studied the 
relationship between regional air trapping and other morphological changes on HRCT with 
air trapping indices (AI). Regional air trapping was present frequently in smokers and in 
Figure 5: Left picture shows normal lung 
tissue compared to dens lung tissue due to 
inflammation on the right side 
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never-smokers with normal lung function; but it was observed in just a few COPD patients. 
Smokers with normal lung function who had regional air trapping on expiratory HRCT had 
significantly lower AI than those without. This sub-group of smokers had better-preserved 
lung function and less emphysema. Lung attenuation on expiratory HRCT and lung 
function expressed as FEV1 and FEV1/FVC were positively correlated to neutrophil 
concentration in BAL. The AI correlated negatively to neutrophil concentration.   
Sub-group of smokers in preclinical stage? 
We demonstrated that HRCT is a powerful tool for assessing early pathological changes in 
smoker’s lung with normal lung function and with no apparent clinical symptoms. 
Although quantitative methods are easily available and time-saving they lack the human 
eye’s sensitivity towards early pathological changes in the lungs. Employing visual 
assessments and densitometry together, however, we were able to separate smokers with 
normal lung function in two distinct sub-groups. One was more susceptible to cigarette 
smoke with decline in lung function and emphysema while the other had preserved both 
function and parenchyma better. One interesting finding was the positive correlation of 
neutrophils to better lung function and preserved lung parenchyma. This finding may 
indicate that the role of neutrophils in pathogenies of COPD should be revised. Probably 
this sub-group of smokers is able to respond to the adverse effect of cigarette smoke better 
than the other. Another possibility can be that the other group was now in more advanced 
stage of preclinical disease. 
 
6 Conclusions 
 
-Cell counts and cell concentration showed a four- to fivefold increase among smokers 
compared to never-smokers and ex-smokers. The cell increase in smokers was due to 
macrophage dominance. The percentage of recovered BAL fluid declined with increased 
age. Female smokers had higher recovered fluid than male smokers. 
 -Morphological changes on HRCT were more frequent in all newly-diagnosed RA than 
among controls. RA patients with positive ACPA had more morphological changes than 
ACPA-negative RA patients. A higher concentration of ACPA in ACPA-positive RA 
patients was demonstrated in BAL than in serum.  
- Lung density in smokers with normal lung function was higher than in never- smokers and 
COPD patients. Increased lung density in smokers with normal lung function was 
positively correlated to increased cell concentration in BAL. Lung density was higher in 
females than males regardless of smoking history.  
- Visual assessment of morphological changes on expiratory and inspiratory HRCT 
combined with lung densitometry was a useful method for dividing smokers into two 
distinct sub-groups. Those with regional air trapping had better lung function and less 
emphysema. AI was higher in smokers without regional air trapping. Neutrophil 
concentration in BAL was positively correlated to AI in smokers. 
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7 FUTURE PLANS AND PERSPECTIVES 
 
Participants in the cross-sectional studies reported in papers III and IV are well 
characterized at baseline. Data has been collected on lung function and inspiratory and 
expiratory HRC, blood samples, bronchial biopsies, BAL fluid etc. A follow-up study 
regarding changes in lung function, lung density and morphological changes shown on 
HRCT within a period of 7-10 years may contribute to the detection of some valuable 
predictive markers for disease progression and severity.   
The participants in study II were newly-diagnosed RA patients examined at baseline with 
HRCT and spirometry. Blood samples were obtained from all and 23 cases underwent 
bronchoscopy and BAL. These base line data were from steroid- and methotrexate-naïve 
patients. A six-month follow-up study on these patients with HRCT and clinical evaluation 
has been already performed and data has been collected for analysis. The analysis may 
answer several important questions concerning the development of morphological changes 
on HRCT, whether they slow down or progress after methotrexate medication – a 
cornerstone of RA therapy – disease progress and other treatment responses in sub-groups 
of ACPA-positive and ACPA-negative RA patients related to pulmonary changes.       
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8 POPULÄRVENSKAPLIG SAMMANFATTNING 
 
Bakgrund 
Cigarettrökning skadar luftvägarna dels genom direkt påverkan på slemhinnan och dels 
genom initiering av en inflammatorisk process som mobiliserar kroppens immunceller till 
att utsöndra skadliga ämnen. Dessa ämnen i sin tur orsakar ytterligare skador både lokalt i 
lungor men även i andra organ, såsom hjärta, kärl och skelett. Den kroniska inflammationen 
i lungor leder till bindvävsomvandling med förträngning av små luftvägar och förlust av 
lungvävnad. Dessa förändringar kan manifestera sig i kroniskt obstruktiv sjukdom (KOL). 
Den inflammatoriska processen kan emellertid också fortskrida i många år utan påtagliga 
symptom eller påverkan på lungfunktionen. Den skadliga effekten av cigarettrök varierar 
starkt mellan olika individer och medför att det kan finnas olika manifestationer av 
tobaksrök hos olika individer, SK fenotyper. Spirometri används för att diagnostisera KOL 
och mäter enbart luftvägsobstruktionen men den ger ingen information om bakomliggande 
orsak till luftflödesbegränsningen. Dessutom ger både tidiga skador i små luftvägar och 
begynnande destruktion av lungvävnad(emfysem) inte utslag på spirometri och förblir ofta 
oupptäckta. 
Rökning är också en känd riskfaktor för den vanligaste autoimmuna sjukdomen, 
ledgångsreumatism, reumatoid artrit (RA). Lungförändringarna på skiktröntgen är vanligt 
förekommande hos dessa patienter och specifika antikroppar mot kroppsegna ämnen, 
sannolikt från lungan, har påträffats hos personer som insjuknat i RA. Dessa antikroppar 
mot citrullinerad peptid (ACPA) kan ibland finnas redan före kliniska symtom.  
Syftet med föreliggande avhandling är att på ett strukturerat sätt kartlägga aspekter 
avrökinducerad inflammation och strukturella förändringar i lungor och luftvägar i ett tidigt 
skede med fokus på två stora folksjukdomar, KOL och RA. 
I delarbete I undersökte vi effekt av rökning på celler i lungsköljvätska, bronkoalveolärt 
lavage (BAL). Detta är en metod med vilken man genom ett smalt fiberoptiskt instrument 
nedförd i lungan, kan skölja upp celler från de djupa luftvägarna. Studien är en retrospektiv 
sammanställning av BAL resultat erhållna under åren 1990-2009  vid vår enhet. 
Etthundratrettiotvå rökare med normal lungfunktion och 44 exrökare inkluderades. 
Tvåhundranittiofem friska aldrigrökare tjänade som kontrollgrupp. Rökare hade cirka fyra 
gånger fler inflammatoriska celler i BAL än både aldrigrökare och exrökare. Den 
kumulativa cigarettkonsumtionen påverkade både totalantal celler och cellkoncentration i 
BAL. Returvolymen vätska minskade med stigande ålder och denna var också mindre hos 
rökande män än rökande kvinnor. Våra resultat kan användas vid tolkning av BAL i 
kliniska sammanhang och poängterer vikten av noggrann bedömning av rökstatus vid 
tolkning av resultat från lungsköljvätska.  
Syftet med delarbete II var att undersöka strukturella och immunologiska förändringar i 
lunga vid nydebuterad reumatoid artrit (RA). Skiktröntgen genomfördes på 105 
  19 
nydebuterade patienter med RA varav 24 även genomgick bronkoskopi inkluderande 
lungsköljning. . Antikroppar mot citullinerad peptid (ACPA+) påvisades hos 70 patienter. 
Fyrtiotre försökspersoner både rökare och aldrigrökare tjänade som kontrollmaterial. 
Lungskiktröntgen bedömdes av två experter och dessa förändringar relaterades till 
förekomst av ACPA+ och rökvanor. Patologiska förändringar i lungor upptäcktes i högre 
grad hos ACPA+ RA patienter (63 %) jämfört med ACPA- (37 %) kontroll (30 %). 
Lungförändringarna visade ingen korrelation till rökstatus. Nivåerna av ACPA var högre i 
lungsköljvätska jämfört med serum hos ACPA+ patienter. Studien visar att 
lungförändringar är vanliga hos RA patienter i tidigt sjukdomsskede och att dessa 
förändringar är korrelerade till förekomst av ACPA. Fynden förstärker hypotesen; att 
autoimmunitet kan initieras i lungor hos ACPA+ RA patienter.  
Syftet med delarbete III var att studera lungtäthet mätt med skiktröntgen hos rökare med 
normal lungfunktion, friska aldrigrökare samt patienter med lindrig till måttlig KOL och att 
utröna om tätheten i rökarnas lungor speglar graden av inflammation i lungvävnad. Fyrtio 
rökare med normal lungfunktion, 40 friska aldrig rökare och 40 KOL patienter genomgick 
skiktröntgen av lunga samt lungsköljning. Lungtätheten var högre hos rökare jämfört med 
friska aldrigrökare och KOL patienter. Cellkoncentrationen i lungsköljvätska var positivt 
korrelerad till lungtäthet hos rökare. Kvinnor hade tätare lungor än män oavsett rökstatus. 
Studien visar att ökad lungtäthet hos rökare kan vara ett tecken på inflammation i lungor 
och att denna går att mäta med skiktröntgen.  
Fyrtio rökare med normal lungfunktion, 40 friska aldrig rökare och 40 KOL genomförde 
skiktröntgen både i in- och utandning. Bilderna bedömdes både kvalitativt och kvantitativt 
av två oberoende experter."Airtrapping index", ett beräknat kvantitativt mått på 
engagemang av små luftvägar, var signifikant lägre hos rökare och aldrig rökare jämfört 
med KOL- patienter. Visuellt bedömd "airtrapping" fanns hos 63 % av rökarna, 45 % av 
aldrigrökarna och 8 % av KOL-patienterna. Emfysem detekterades hos 80 % av KOL-
patienterna och 55 % av rökarna. Mikronoduli (små diffusa tunna förtätningar) fanns hos 58 
% av rökarna och 38 % av KOL-patienterna. Bronkväggsförtjockning förekom hos 75 % av 
rökarna och 80 % av KOL-patienterna. Det saknades emfysem och mikronoduli hos 
aldrigrökarna men 12 % hade bronkväggsförtjockning. De rökare som hade tecken på 
visuell ” air trapping” hade bättre bevarad lungfunktion och mindre emfysem jämfört med 
rökarna utan. "Airtrapping index" visade negativ korrelation med neutrofila granulocyter, 
en viktig inflammatorisk cell, i lungsköljvätska.  
Sammanfattningsvis har vi studerat inflammatoriska och strukturella förändringar i lungor 
hos rökare, KOL-patienter och RA patienter med hjälp av analys av skiktröntgen och 
lungsköljvätska. Dessa förändringar finns även i ett tidigt icke symtomgivande stadium hos 
rökare. Studierna visar att strukturella förändringar vid rökrelaterade sjukdomar är 
heterogena. Våra resultat ökar kunskaper om rökningens effekter på lungan som målorgan 
och påvisar att utfallet av rökning hos den enskilda patienten kan skilja sig åt.       
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